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 S U M M A R Y  
  
In Parkinson’s disease (PD) rating scales are used to assess the degree of disease-related disability 
and to titrate long-term treatment to each phase of the disease. Recognition of nonmotor symptoms 
required modification of existing widely used scales to integrate nonmotor elements. In addition, 
new scales have been developed for the assessment of nonmotor symptoms. In this article, 
assessment of PD patients will be discussed, particularly  for nonmotor symptoms as pain and 
fatigue.  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
  
1. Introduction  
Parkinson’s disease (PD) is a common progressive neurodegenerative disorder in which dopamine 
(DA) deficiency arises as a consequence of degeneration in the substantia nigra. The clinical diagnosis 
of PD rests on the identification of motor symptoms as bradykinesia, tremor, rigidity and loss of 
postural reflexes [1]. Recent neuropathological studies, however, have revealed that neuronal loss 
occurs beyond the dopaminergic system, and consequently patients display non-motor symptoms 
(NMS) [2]:  
a. Neuropsychiatric symptoms (depression, apathy, anxiety, anhedonia, deficits in attention, 
hallucinations, dementia, obsessional behaviour, confusion, panic attacks)  
b. Autonomic symptoms (bladder disturbances, sweating, orthostatic hypotension, sexual 
dysfunction)  
c. Gastrointestinal symptoms (constipation, salivation, loss of taste, dysphagia)   
d. Sensory symptoms (pain, paraesthesia, olfactory disturbance);   
e.  Sleep disorders (restless legs and periodic limb movements, rapid eye movement (REM) sleep 
disorder, non-REM-sleep related movement disorders, excessive daytime somnolence);   
f. Other symptoms (fatigue, diplopia, blurred vision, seborrhoea, weight loss).  
Although NMS correlate with advancing age and disease severity, some non-motor symptoms such 
as olfactory problems, constipation, depression, and rapid eye movement disorder, can occur early in 
the disease. These symptoms are increasingly recognized to precede motor symptoms by many years 
as the pre-motor (pre-symptomatic) stage of PD [2]. The neuroanatomical and neurochemical 
substrates for the non-motor symptom complex in Parkinson’s disease remained unknown until the 
breakthrough made by Braak and colleagues, who introduced the concept of a six-stage pathological 
process putting extranigral structures in the centre of interest (dorsal motor vagus nucleus, olfactory 
bulb, the serotonergic raphe nuclei, cholinergic brainstem complex) [3]. Despite this emphasis on 
motor symptomatology, several studies have shown that the NMS of Parkinson’s disease have 
greater significance when assessed by Quality-of-life measures, institutionalization rates, and health 
economics.  
  
2. Clinical rating scales  
Although, both PET and SPECT scanning are sensitive enough to detect a subclinical degeneration of 
the DA system, nuclear imaging techniques are costly, and frequently not widely available for 
screening for premotor PD. Therefore, the patient’s medical history and neurological assessment 
form the basis for making a PD diagnosis. PD is usually diagnosed when motor symptoms appear, but 
many patients will in hindsight recall a prodromal phase including non-motor symptoms.   
Clinicians use several subjective rating scales to evaluate PD patients in order to make a correct 
diagnosis. In addition, the increasing number of therapeutic interventions in PD has highlighted the 
importance of measuring clinical outcome. Thus, in PD, rating scales are used to assess the degree of 
disease-related disability and progression, to monitor patient care, and to titrate long-term 
treatment in each phase of the disease. Simple but reproducible rating scales are essential and 
clinicians should be widely aware of these scales and know how and when to use them. Those that 
fulfil such conditions are the Hoehn and Yahr scale (HY) [4], the Schwab and England scale [5], and 
the Unified Parkinson’s Disease Rating Scale (UPDRS) [6, 7].  
The UPDRS is the most widely used, having proven intra and inter-observer validity. It is a 
standardized clinical assessment that is used to document both disease progression and response to 
treatments. This four tiered scale, with particular emphasis on motor measurement, provides a 
detailed evaluation of:  
I, Nonmotor Experience of Daily Living; II, Motor Experience of Daily Living; III, Motor Examination; 
IV, Motor Complications   
The 5-stage HY scale is used to classify patients based on the severity of symptoms and ability to live 
independently.   
The Schwab and England scale can be used by patients, family members or health care providers to 
assess the impact of PD on independent living skills.   
 2.1. Clinical rating scales: non-motor symptom  
  
The great importance of the accurate detection and evaluation of NMS in PD was recognized by the 
Movement Disorders Society (MDS) who sponsored a revision of the original UPDRS that was 
developed in the 1980s [6]. The MDS-UPDRS retains the UPDRS structure of four parts, but these 
have been modified to provide a section that integrates nonmotor elements of PD [7]. In addition, 
the clinical significance of NMS in PD resulted in development of a new 30-item rating scale, the Non-
Motor Symptoms assessment scale for Parkinson’s disease (NMSS) [8]. Data from nine domains 
provides information on the following systems: cardiovascular, sleep/fatigue, mood/cognition, 
perceptual problems, attention/memory, gastrointestinal, urinary, sexual function, and 
miscellaneous. The scale is easy to administer, reproducible, and has acceptable clinical accuracy. 
There is a significant relationship between NMSS score and severity of disease based on HY scale. 
Furthermore, the growing interest in non-motor aspects of the disease is exemplified by publications 
of specific, validated, Parkinson’s disease scales for the assessment of such specific NMS domains as 
autonomic function (SCOPA-AUT) [9], sleep (Parkinson’s disease sleep scale, SCOPA-sleep) [10], 
cognitive function (Parkinson’s Disease-Cognitive Rating Scale) [11], depression (Beck depression 
inventory) [12], and fatigue [13]. In chronic neurological diseases such as PD, one requires knowledge 
of the impact of the illness on the patient’s life. Thus, quality of life (QoL) questionnaires have been 
developed to measure the impact of the disease on general well-being that cannot be assessed by 
rating scales [14].  
  
3. Sensory dysfunctions   
There is a wide spectrum of sensory symptoms in PD but only olfactory disturbance, visual 
impairment and pain are characteristic sensory features in the disease. These symptoms may 
precede the motor phase, but only olfactory testing is considered currently to be a potential 
preclinical marker for PD [2].   
 3.1. Pain  
Although pain is a prominent NMS in PD it has not been well studied. It was usually considered that 
pain was due to secondary causes such as being of musculoskeletal origin, or related to motor 
fluctuations and dystonia. Sometimes, secondary pain is relieved by levodopa, indicating that it 
should be considered as part of the spectrum of NMS. However, attention is now being focused on 
the recognition and quantization of pain as NMS [2]. The NMS of PD is frequently overlooked by 
neurologists if quantitative assessment and rating instruments are not used, and this is especially 
true in the setting of pain. Implementation of the NM self-completed questionnaires, Visual 
Analogue Scale and/or McGill questionnaire [15, 16] in clinical practice indicate that pain may 
precede the diagnosis of PD and that 'shoulder pain' could be a presenting symptom.   
Our study investigating NMS in 56 de-novo PD patients showed that the most frequent NMS was 
depression, as expected (43.3 %), followed by constipation (35.3 %) and unexplained pain (29.3 %), 
mostly in the shoulder region (17). Our results indicate that the NMS questionnaire was effective in 
pain assessment in de-novo PD patients. In addition, quantitative assessments of pain in chronic PD 
patients on long-term therapy with motor complications can reveal the association between pain and 
different clinical variables. Tables 1 and 2 show the association between pain and various 
demographic and clinical variables in 43 PD patients (21 with pain and 23 without pain). Patients with 
pain showed a significantly higher mean levodopa dose, more severe motor complications, and a 
more frequent use of sleeping pills. There was no difference between patients with predominantly 
akinetic-rigid type PD, and those with tremor, and no difference for those with left, right or 
symmetric symptom dominance. The most important finding was that there was no difference in 
depression and cognition scores between the groups with and without pain. Thus quantitative 
assessments of pain indicate the presence of pain in PD both as a prodromal sign, as well as a 
comorbid condition in the later stage of the disease.  
  
4. Neuropsychiatry   
The cognitive and neuropsychiatric NMS of PD range from apathy, anxiety and panic attacks to 
depression, psychosis, mild cognitive impairment, and dementia. Most of the neuropsychiatric 
disorders develop in the later stage of the disease and/or occur as side-effects of medications. 
Psychotic symptoms and dementia strongly correlate with the need for nursing home placement. 
Depression is the most significant predictor of quality of life in PD patients, and is present in 10-45% 
of patients with PD. It is considered that depression could be one of the presenting symptoms of PD 
that predate motor symptoms [1, 2].  
  
4.1. Fatigue  
Chronic fatigue is reported in more than 20% of people in primary care. Fatigue is a typical symptom 
of neurological disease, but still poorly understand. Although often recognized as a sign or symptom 
of a disease, or a side effect of treatment, fatigue is a subjective experience. In the absence of a 
biological marker or gold standard for defining fatigue, assessment of fatigue represents a great 
challenge. Fatigue may be an important determinant of quality of life and physical disability in PD 
and it is underestimated in terms of its negative impact on patient well-being [18]. It has been shown 
that fatigue is a consistent and common but underdiagnosed problem in PD patients. Several studies 
investigating fatigue in PD have been published but often have used different rating scales [19, 20]. 
The MDS task force recently evaluated available clinical rating scales for fatigue (Table 3) [13]. A scale 
that demonstrates sensitivity to changes in PD specifically rather than in other areas is 
'recommended'. If a scale failed to meet all the criteria of a recommended scale, it was 'suggested'. 
Scales were 'listed' if they had been used in PD studies but had little or no psychometric data to 
assess. Some scales could be used both to screen for fatigue, as well as to assess severity. Only the 
Fatigue Severity scale was 'recommended' for both screening and severity rating.    
  
5. Concluding comments  
There is a wide range of motor and non-motor symptoms that occur in Parkinson's disease, and 
consequently it is difficult for a single instrument to encompass the whole spectrum of symptoms, 
possibly explaining why many different rating scales have been developed. The main purpose of each 
scale is to be simple to use, reproducible, to have acceptable clinical precision and accuracy, and to 
be available for clinicians dealing with patients with movement disorders. NMS cause problems in 
the daily life of PD patients and have a great impact on the quality of life, but they are usually 
underdiagnosed and are not adequately treated. To improve the treatment of PD patients, both 
motor as well as non-motor symptoms should be assessed using well-validated rating scales and 
questionnaires.  
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Table 1 
 
Demographic and clinical data for patients with Parkinson's disease with and without pain 
 
 With pain 
mean (SD) 
N=21 
Without pain 
mean (SD) 
N=23 
 
p values 
Age (years) 
Duration of disease (years) 
MMSE score 
BDI score 
VAS 
UPDRS motor score 
Hoehn and Yahr 
Levodopa dose (mg/day) 
68.3 (6.5) 
10.3 (5.5) 
23.7 (5.5) 
12.6 (8.7) 
36.1 (9.7) 
22.7 (12.0) 
2.8 (1.0) 
591.7 (263.1) 
69.1 (7.3)  
9.7 (4.5) 
22.9 (3.5) 
11.9 (7.1) 
83.4 (12.3) 
21.9 (11.9) 
2.6 (1.1) 
474.5 (215.3) 
0.50 
0.59 
0.50 
0.53 
0.001 
0.47 
0.57 
0.005 
 
MMSE, Mini Mental Status Examination; BDI, Beck Depression Inventory; VAS, Visual 
Analogue Scale; UPDRS, Unified Parkinson's Disease Rating Scale;  
Mann-Whitney test 
 
 
Table 2 
 
Demographic and clinical data for patients with Parkinson's disease with and without pain 
 
 With pain 
no (%) 
N=21 
Without pain 
no (%) 
N=23 
 
p values 
Gender 
Dexterity of symptoms 
     Right 
     Left 
     Symmetry 
Disease type 
     Akinetic 
     Tremor 
     Mixed 
Motor complications 
Sleeping pils 
11 (52.3) 
 
12 (57.1) 
8 (38.1) 
1 (4.7) 
 
4 (19) 
2 (9.5) 
15 (71.4) 
15 (71.4) 
13 (61.9) 
12 (57.1) 
 
11 (52.3) 
10 (47.6) 
2 (9.5) 
 
4 (19) 
3 (14.3) 
16 (76.2) 
6 (28.6) 
10 (47.6) 
0.5 
 
 
0.37 
 
 
 
0.5 
 
0.001 
0.005 
 
Chi – square test for frequency 
 
Table 3 
 
Fatigue rating scales review 
 
Scale name Recommended Suggested Listed 
Fatigue severity scale 
Screening 
Severity 
+ 
+ 
  
Fatigue Assessment Inventory 
Screening 
Severity 
 + 
+ 
 
The Functional Assessment of 
Chronic Illness Therapy-Fatigue 
Screening 
Severity 
+ 
+ 
 
The Multidimensional  
Fatigue Inventory 
Screening 
Severity + 
+  
Parkinson Fatigue Scale 
Screening 
Severity 
+ 
+ 
 
Fatigue Severity Inventory 
Screening 
Severity 
  + 
+ 
Fatigue Impact Scale  
for Daily Use 
Screening 
Severity 
 
+ 
+ 
Visual Analogue Scale 
Screening 
Severity 
  + 
+ 
Global Impression Scale 
Screening 
Severity 
  + 
+ 
 
Adapted from Friedman et al. [13] 
